Docrates Cancer Center becomes part of Mehiläinen

At Docrates Cancer Center, people with cancer receive individualised service under one roof throughout the entire treatment and monitoring period. The company’s operations emphasise individual cancer treatments with no delay, as well as high quality, education and research. Docrates has a hospital in Helsinki, where more than 130 cancer treatment professionals provide services. As a private cancer hospital, Docrates is a pioneer in Europe and the only one of its kind in the Nordic countries. In addition to Finland, people seek Docrates' services from up to 50 different countries each year, including Sweden and Norway. Docrates now becomes part of Mehiläinen through the acquisition.

- We are very excited to continue to develop high-quality cancer treatment services together with Docrates. As a pioneer in cancer treatment, Docrates has built a unique treatment center on both Finnish and international standards and wants to maintain the latest research and treatment methods in its operations. At Mehiläinen, we want to serve our customers holistically and offer a high-quality treatment chain for cancer as well. This is now possible for us through Docrates Cancer Center, says Janne-Olli Järvenpää, CEO of Mehiläinen Group.

- For 15 years, we have been proud to build and support Docrates’ success story as an international, state-of-the-art cancer hospital. This pioneering journey has been amazing. For Docrates, the next natural step in the development of our operations is internationalisation. We are convinced that Mehiläinen’s strong domestic traditions and current international organisation will provide the right home for Docrates for the next phase of growth. In my opinion, Finland now needs precisely these kinds of initiatives that enable innovative pioneering companies to internationalise, grow and employ. The Aava Terveyspalvelut group is a strong national player in the field of healthcare, and in future we will focus on developing the business of Lääkärikeskus Aava, Pikkujätti and Aisti Health, says Antti Aho, CEO of Docrates' former largest owner, Aava Terveyspalvelut Oy.

- Through its extensive network and resources, Mehiläinen gives Docrates the opportunity to offer the latest cancer diagnostics and treatments to an increasingly large customer group, both in Finland and in other countries. We plan to, for instance, open a new clinic in Stockholm. I also believe that Docrates' strong approach of "people standing by people" fits perfectly with Mehiläinen's long-established traditional Finnish corporate culture, says Ilpo Tolonen, CEO of Docrates.

In future, Docrates and Mehiläinen will continue their joint investments in improving service quality, expanding their operations, and educating and training specialists. The aim is for Docrates to continue its strong research work and provide cancer treatments based on the latest research to its customers.

In future, Mehiläinen’s comprehensive service network will give customers even smoother access to services. With Mehiläinen, we can offer our customers more extensive rehabilitation-supporting physiotherapy, mental health support and other forms of therapy. Mehiläinen’s international organisation and capabilities give us broader resources to grow our operations, even outside of Finland.

Docrates' operations will continue as before at the company’s hospital in Ruoholahti, Helsinki. Docrates' employees and professionals will continue as old employees and private practitioners with their previous contracts after the acquisition. The transaction requires the approval of the competition authorities in order to take place.